Dyadic International (DYAI) Total Current Liabilities (2017 - 2026)
Dyadic International's (DYAI) quarterly Total Current Liabilities came in at $3.2 million in Q1 2026, up 62.26% year-over-year from $2.0 million in Q1 2025, and down 13.65% quarter-over-quarter from $3.7 million in Q4 2025.
Analysis
Dyadic International (DYAI) Total Current Liabilities (2017 - 2026) Analysis & Trends
Dyadic International has disclosed Total Current Liabilities across 10 years of filings, most recently posting $3.2 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 62.26% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (up 62.26% YoY), while the FY2025 annual figure was $3.7 million, up 50.62% from the prior year.
- Total Current Liabilities came in at $3.2 million for Q1 2026 at Dyadic International, down from $3.7 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $1.8 billion in Q1 2022 to a low of $1.5 million in Q3 2023.
- Average Total Current Liabilities over 5 years is $109.9 million, with a median of $2.4 million recorded in 2022.
- Year-over-year, Total Current Liabilities soared 70319.08% in 2022 and sank 99.9% in 2023.
- Over 5 years, Total Current Liabilities stood at $2.4 million in 2022, then fell by 8.04% to $2.3 million in 2023, then climbed by 8.71% to $2.4 million in 2024, then surged by 50.62% to $3.7 million in 2025, then dropped by 13.65% to $3.2 million in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $3.2 million in Q1 2026, $3.7 million in Q4 2025, and $4.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 25.50 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 11.02 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 3.94 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 5.53 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.58 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 2.53 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 3.92 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 283.60 Mn |
| 10 | Dyadic International | 17.78 Mn | 9.82 Mn | - | 3.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 3.18 Mn |
| Dec 31, 2025 | 3.69 Mn |
| Sep 30, 2025 | 4.05 Mn |
| Jun 30, 2025 | 3.66 Mn |
| Mar 31, 2025 | 1.96 Mn |
| Dec 31, 2024 | 2.45 Mn |
| Sep 30, 2024 | 2.08 Mn |
| Jun 30, 2024 | 1.95 Mn |
| Mar 31, 2024 | 2.26 Mn |
| Dec 31, 2023 | 2.25 Mn |
| Sep 30, 2023 | 1.46 Mn |
| Jun 30, 2023 | 2.00 Mn |
| Mar 31, 2023 | 1.88 Mn |
| Dec 31, 2022 | 2.45 Mn |
| Sep 30, 2022 | 2.39 Mn |
| Jun 30, 2022 | 3.40 Mn |
| Mar 31, 2022 | 1.83 Bn |
| Dec 31, 2021 | 2.56 Mn |
| Sep 30, 2021 | 1.96 Mn |
| Jun 30, 2021 | 3.29 Mn |